Author/Authors :
Çayır, Kerim Atatürk Üniversitesi - Tıp Fakültesi - Medikal Onkoloji Bilim Dalı, Turkey , Bilici, Mehmet Atatürk Üniversitesi - Tıp Fakültesi - Medikal Onkoloji Bilim Dalı, Turkey , Tekin, Salim Başol Atatürk Üniversitesi - Tıp Fakültesi - Medikal Onkoloji Bilim Dalı, Turkey , Emre, Habip Atatürk Üniversitesi - Tıp Fakültesi - İç Hastalıkları Anabilim Dalı, Turkey , Bilen, Yusuf Atatürk Üniversitesi - Tıp Fakültesi - İç Hastalıkları Anabilim Dalı, Turkey
Abstract :
Objectives: The aim of this study was to evaluate compliance of the stage II-III colon cancer patients to the adjuvant chemotherapy and to investigate the results of adjuvant chemotherapy in terms of toxicity in the same group of patients. Materials and Methods: Operated, stage II and III colorectal cancer patients post-operatively followed in Department of Internal Medicine, Division of Medical Oncology between December 2000 and December 2007 were enrolled into this study. Patients who were diagnosed as rectal cancer or who had metastases were excluded. Eleven (21.6%) of the 51 patients either did not accept chemotherapy or adjuvant chemotherapy was not offered. Thirty (58.8%) patients treated with FUFA (5 Fluoro-urasil/ leucoverin) chemotherapy regimen and the resting 10 (19.9%) patients were treated with FOLFOX (Oxaliplatin/5 Fluoro-urasil/leucoverin) chemotherapy regimen. Toxicities that emerged after treatment and patient adherence to treatment was evaluated. Results: Patients who were treated with FUFA chemotherapy regimen had better percentages of chemotherapy regimen completion, lesser mucositis and diarrhea rates, except neutropenia and neutropenic fever. Evaluation of patients who were treated with FOLFOX chemotherapy regimen that includes oxaliplatin revealed that completion of chemotherapy regimen rate and chemotherapy-associated diarrhea rates were similar with the literature. There were differences between our results and literature in rates of neutropenia, neutropenic fever and neuropathy. Conclusions: Less adverse effects were seen in adjuvant chemotherapy application of operated colorectal cancer patients with either stage II or stage III.
